Experimental cell therapy trial offers hope for lymphoma patients who have run out of options
NCT ID NCT05618925
Summary
This early-stage study is testing a new cell therapy called CD19 t-haNK, both alone and combined with other drugs, for adults with non-Hodgkin lymphoma that has come back or stopped responding to standard treatments. The main goal is to check the safety of this new approach and see if it shows any signs of helping to control the cancer. About 20 participants will receive the therapy after a short course of chemotherapy to prepare their body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN'S LYMPHOMA REFRACTORY/RELAPSED are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hoag Memorial Hospital
RECRUITINGNewport Beach, California, 92663, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Texas Oncology
RECRUITINGTyler, Texas, 75702, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.